The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple Myeloma

Overview

There is a growing body of data suggesting that the the risk of developing multiple myeloma, or myelomagenesis, is associated with genetic alterations occurring in the tumor cells. A limited number of candidate genes and polymorphisms have been reported in patients with this disease. In this study the investigators will compare the genetic information obtained on purified abnormal plasmocytes obtained from patients with multiple myeloma with available public databases in an effort to identify and if possible validate the role of certain mutations and/or polymorphisms in myelomagenesis. Plasmocytes will be obtained by immunomagnetic enrichment using CD138+ beads.

Full Title of Study: “Analysis of Genomic Alterations in Sporadic Cases of Multiple Myeloma”

Study Type

• Study Type: Observational
• Study Design
  • Time Perspective: Prospective
• Study Primary Completion Date: December 1, 2023

Interventions

• Genetic: DNA sequencing
  • The aim of this study is to perform DNA sequencing on abnormal plasmocytes obtained from patients with multiple myeloma, in order to identify alterations which are associated with the existence of this disease. DNA analyses will be performed in a single experiment once all samples have been collected.

Arms, Groups and Cohorts

• patients with a diagnosis of multiple myeloma
  • This study will involve a single patient group, namely patients with a diagnosis of multiple myeloma diagnosed by a bone marrow aspirate with cytological analysis of the bone marrow smear.Bone marrow samples obtained during the routine follow-up will undergo plasmocyte enrichment using immunopurification using CD138+ beads and nucleic acids will be extracted for sequencing.

Clinical Trial Outcome Measures

Primary Measures

• DNA mutations associated with the existence of multiple myeloma
  • Time Frame: baseline, pre-intervention/procedure/surgery
  • DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases.
• DNA mutations associated with the existence of multiple myeloma
  • Time Frame: during the intervention/procedure/surgery
  • DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases.
• DNA mutations associated with the existence of multiple myeloma
  • Time Frame: immediately after the intervention/procedure/surgery
  • DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases.
• DNA mutations associated with the existence of multiple myeloma
  • Time Frame: at 1 year
  • DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases.
• DNA mutations associated with the existence of multiple myeloma
  • Time Frame: up to 24 weeks
  • DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases.
• DNA mutations associated with the existence of multiple myeloma
  • Time Frame: through study completion, an average of 1 year
  • DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases.

Participating in This Clinical Trial

Inclusion Criteria

• diagnosis of multiple myeloma – availability of abnormal plasmocytes Exclusion Criteria:

• none

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

• Lead Sponsor
  • Hospices Civils de Lyon
• Provider of Information About this Clinical Study
  • Sponsor
• Overall Contact(s)
  • Charles DUMONTET, Pr, 04 78 46 83 40, charles.dumontet@chu-lyon.fr